Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices.
Aniek DaneAnne-Sophie Klein GebbinkJan-Dietert BrugmaAlbane Degrassat-ThéasMartin J HugMorten B HoulindP PaubelP Hugo M van der KuyCarin A Uyl-de GrootPublished in: Applied health economics and health policy (2023)
No evident price drops of included brand-name OMPs were observed around MEE and differences in purchase prices are modest in the selected Western European countries. Results were not subject to significance testing. More robust data are needed to strengthen negotiations with suppliers.